Combining structure-based drug designing methodology with in vitro studies, scientists have been able to identify a FDA-approved molecule that shows enhanced anti-kala-azar activity.
Three active inhibitor molecules were selected from the PubChem database and one of them showed the highest stability in binding to the active sites of the target enzyme (UDP-galactopyranose mutase or UGM) which helps in the formation of glycoprotein, beta-Galf. After binding to the UGM, the molecule inhibits the enzyme activity thereby reducing the virulence, parasite survival and transmission of disease. The results were published in the Journal of Cellular Biochemistry.
Treatment for kala-azar (disease caused by Leishmania infection) is limited due to high toxicity to human cells, low efficacy of the drug, high cost and drug resistance making the development of novel anti-kala-azar drugs a priority....Read more
Source web page:The Hindu